JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

CareDx Inc

Abrir

SetorSaúde

14.89 1.85

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.5

Máximo

15.15

Indicadores-chave

By Trading Economics

Rendimento

1.8M

-8.6M

Vendas

2M

87M

P/E

Médio do Setor

13.819

37.003

Margem de lucro

-9.885

Funcionários

644

EBITDA

9.3M

-4M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+22.7% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

71M

772M

Abertura anterior

13.04

Fecho anterior

14.89

Sentimento de Notícias

By Acuity

80%

20%

347 / 373 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

CareDx Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de out. de 2025, 23:50 UTC

Ações em Alta

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 de out. de 2025, 23:25 UTC

Ganhos

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 de out. de 2025, 23:18 UTC

Ganhos

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 de out. de 2025, 22:20 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 de out. de 2025, 22:13 UTC

Ganhos

Wal-Mart de Mexico Net Profit Falls in 3Q

28 de out. de 2025, 21:38 UTC

Ganhos

Correction to Visa Sales Jump Article

28 de out. de 2025, 21:17 UTC

Ganhos

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 de out. de 2025, 21:07 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- Update

28 de out. de 2025, 21:02 UTC

Ganhos

Mondelez Tempers Outlook as Costs Rise

28 de out. de 2025, 23:51 UTC

Conversa de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 de out. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 de out. de 2025, 23:02 UTC

Ganhos

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 de out. de 2025, 23:01 UTC

Ganhos

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 de out. de 2025, 22:46 UTC

Ganhos

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 de out. de 2025, 22:45 UTC

Ganhos

SK Hynix 3Q Net KRW12.6T >000660.SE

28 de out. de 2025, 22:44 UTC

Ganhos

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 de out. de 2025, 22:43 UTC

Ganhos

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 de out. de 2025, 22:42 UTC

Ganhos

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 de out. de 2025, 22:20 UTC

Ganhos

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 de out. de 2025, 22:02 UTC

Ganhos

Review & Preview: Earnings Extravaganza -- Barrons.com

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 de out. de 2025, 21:20 UTC

Ganhos

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 de out. de 2025, 21:19 UTC

Ganhos

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 de out. de 2025, 21:18 UTC

Ganhos

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparação entre Pares

Variação de preço

CareDx Inc Previsão

Preço-alvo

By TipRanks

22.7% parte superior

Previsão para 12 meses

Média 18 USD  22.7%

Máximo 22 USD

Mínimo 14 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para CareDx Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

2

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

14.77 / 18.49Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

347 / 373 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat